Pharmacologic reversion of Merkel cell carcinoma via CBP/p300 inhibition
Proceedings of the National Academy of Sciences · 2025
DOI: 10.1073/pnas.2516667122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Joseph L Collura und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Virology Program, University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA 15213. Hauptthemen laut MEDLINE: Carcinoma, Merkel Cell, E1A-Associated p300 Protein, CREB-Binding Protein, Skin Neoplasms. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Deutschen Konsortium für Translationale Krebsforschung (DKTK), University of Pittsburgh (Pitt), NCI NIH HHS.
Abstract (Originalsprache)
Merkel cell polyomavirus (MCV) T antigen functions as an oncoprotein that drives the transformation of Merkel cell carcinoma (MCC) cells by activating transcription factors involved in cell proliferation. The viral T antigen promoter requires the activity of the cellular coactivator CREB-binding protein (CBP)/p300 for its expression. Inhibition of CBP/p300 with two distinct small-molecule inhibitors suppresses T antigen expression, leading to cell cycle arrest and upregulation of the cell cycle inhibitor p27 Kip1 . This shift promotes neuronal differentiation, associated with neurite outgrowth in MCC cells. RNA sequencing revealed downregulation of genes involved in E2F, Myc, mTORC1 oncogenic signaling, as well as markers of the Merkel cell lineage including Sox2 and Atoh1. Notably, a rare MCC case exhibiting a mixed cellular composition, with loss of T antigen expression and neuroblastic phenotype, showed a transcriptomic profile resembling that of MCC cells treated with CBP/p300 inhibitors. This suggests that similar differentiation processes may contribute to tumor heterogeneity in patients. This study presents the model system enabling reversible switching between a transformed and differentiated cell state in a human cancer using small-molecule treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Virology Program, University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA 15213.
- Translational Skin Cancer Research, German Cancer Consortium, University Medicine Essen, Essen 45141, Germany.
- German Cancer Consortium, German Cancer Research Center, Heidelberg 69129, Germany.
- "Biologie des infections à polyomavirus" Team, Université de Tours, Tours 37380, France.
- Department of Human Genetics, University of Pittsburgh, Pittsburgh, PA 15260.
- Department of Pathology, University of Pittsburgh, Pittsburgh, PA 15261.
ORCID-Profile: Kuan Cheok Lei, Mitalee Chandra, Thibault Kervarrec, Hyun Jung Park, Mazdak Dalkoohi, Jürgen C Becker, Yuan Chang, Patrick S Moore, Masahiro Shuda
Förderung
- Deutschen Konsortium für Translationale Krebsforschung (DKTK)
- University of Pittsburgh (Pitt)
- NCI NIH HHS
- NIAID NIH HHS
- HHS | NIH | National Cancer Institute (NCI)
Zitieren
APA
Collura, J. L., Lei, K. C., Chandra, M., Kervarrec, T., Park, H. J., Dalkoohi, M., Becker, J. C., Chang, Y., Moore, P. S., & Shuda, M. (2025). Pharmacologic reversion of Merkel cell carcinoma via CBP/p300 inhibition. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2516667122
Vancouver
Collura JL, Lei KC, Chandra M, Kervarrec T, Park HJ, Dalkoohi M, et al. Pharmacologic reversion of Merkel cell carcinoma via CBP/p300 inhibition. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2516667122
BibTeX
@article{Collura2025,
author = {Collura, Joseph L and Lei, Kuan Cheok and Chandra, Mitalee and Kervarrec, Thibault and Park, Hyun Jung and Dalkoohi, Mazdak and Becker, Jürgen C and Chang, Yuan and Moore, Patrick S and Shuda, Masahiro},
title = {Pharmacologic reversion of Merkel cell carcinoma via CBP/p300 inhibition},
journal = {Proceedings of the National Academy of Sciences},
year = {2025},
doi = {10.1073/pnas.2516667122}
}
EUVIMED